David A. Rosa's most recent trade in NeuroOne Medical Technologies Corp was a trade of 2,458 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.68 per share. | 30 Jun 2025 | 2,458 | 1,158,831 | - | 0.7 | 1,667 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2025 | 750,000 | 750,000 | - | - | Option to Purchase Common Stock | |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.50 per share. | 04 Apr 2025 | 100,000 | 1,161,289 | - | 0.5 | 50,000 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.85 per share. | 31 Mar 2025 | 2,458 | 1,061,289 | - | 0.9 | 2,090 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.16 per share. | 18 Feb 2025 | 71,325 | 1,063,747 | - | 1.2 | 82,737 | Common Stock |
| BioRestorative Therapies Inc | David A. Rosa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 52,632 | 52,632 | - | - | Stock Option | |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.15 per share. | 31 Jan 2025 | 2,239 | 1,135,072 | - | 1.2 | 2,575 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.83 per share. | 31 Dec 2024 | 4,697 | 1,137,311 | - | 0.8 | 3,880 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.62 per share. | 30 Nov 2024 | 2,239 | 1,142,008 | - | 0.6 | 1,395 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.97 per share. | 31 Oct 2024 | 2,239 | 1,144,247 | - | 1.0 | 2,172 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.99 per share. | 30 Sep 2024 | 4,697 | 1,146,486 | - | 1.0 | 4,650 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.80 per share. | 31 Aug 2024 | 2,239 | 1,151,183 | - | 0.8 | 1,783 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.75 per share. | 31 Jul 2024 | 2,239 | 1,153,422 | - | 0.7 | 1,679 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.80 per share. | 30 Jun 2024 | 4,697 | 1,155,661 | - | 0.8 | 3,758 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.93 per share. | 31 May 2024 | 2,239 | 1,160,358 | - | 0.9 | 2,082 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 30 Apr 2024 | 2,239 | 1,162,597 | - | 1.1 | 2,530 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.15 per share. | 21 Apr 2024 | 19,673 | 1,164,836 | - | 1.2 | 22,624 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 31 Mar 2024 | 2,239 | 1,184,509 | - | 1.2 | 2,687 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.21 per share. | 29 Feb 2024 | 2,239 | 1,186,748 | - | 1.2 | 2,709 | Common Stock |
| NeuroOne Medical Technolog... | David Rosa A. | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2024 | 663,497 | 1,188,987 | - | 0 | Common Stock | |
| BioRestorative Therapies Inc | David Rosa A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 79,646 | 79,646 | - | - | Stock Option | |
| NeuroOne Medical Technolog... | A. David Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.25 per share. | 31 Jan 2024 | 2,239 | 525,490 | - | 1.3 | 2,799 | Common Stock |
| NeuroOne Medical Technolog... | A. Rosa David | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.58 per share. | 31 Dec 2023 | 2,239 | 527,729 | - | 1.6 | 3,538 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.45 per share. | 30 Nov 2023 | 2,239 | 529,968 | - | 1.5 | 3,247 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.02 per share. | 31 Jul 2023 | 2,239 | 541,163 | - | 1.0 | 2,284 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 30 Jun 2023 | 2,239 | 543,402 | - | 1.2 | 2,687 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.21 per share. | 31 May 2023 | 2,239 | 545,641 | - | 1.2 | 2,709 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.54 per share. | 30 Apr 2023 | 2,239 | 547,880 | - | 1.5 | 3,448 | Common Stock |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2023 | 91,500 | 91,500 | - | - | Option to Purchase Common Stock | |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2023 | 91,500 | 550,119 | - | 0 | Common Stock | |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.61 per share. | 31 Mar 2023 | 2,239 | 458,619 | - | 1.6 | 3,605 | Common Stock |
| Biotricity Inc | David A. Rosa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2023 | 75,930 | 474,683 | - | - | Option (right to buy) | |
| BioRestorative Therapies Inc | David A. Rosa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 32,028 | 32,028 | - | - | Stock Option | |
| NeuroOne Medical Technolog... | David A. Rosa | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.47 per share. | 03 Feb 2023 | 53,750 | 460,858 | - | 1.5 | 79,013 | Common Stock |
| BioRestorative Therapies Inc | David A. Rosa | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Nov 2022 | 10,490 | 0 | - | - | Stock Option | |
| BioRestorative Therapies Inc | David A. Rosa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2022 | 10,490 | 10,490 | - | - | Stock Option |